Catalyst Wire Dossier Catalyst Wire Dossier

Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination (SOF/VEL/VOX FDC)

· Gilead Sciences
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination (SOF/VEL/VOX FDC), covering 2020-08-31 to 2020-08-31. Get the full timeline:

Most recent: Clinical Trial Update: Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection [Phase 2]

See pricing